Transient Ischemic AttackDAITSUNCT07339787
Diagnosis of Transient Ischemic Attacks in the Emergency Department
An observational study of Transient Ischemic Attack and Cardiovascular Morbidity, run by University Hospital, Strasbourg, France at 1 site in France.
Trial summary
Patients presenting a Transient Ischemic Attack (TIA) and admitted to the Emergency Department should be referred to a neurovascular specialist. In recent years, several hospitals have established TIA clinics. These units are day hospitals where all the necessary examinations are performed. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Transient Ischemic Attack, Cardiovascular Morbidity
- How many people
- 300 participants
- Where
- 1 siteFrance
- Study dates
- 6 Feb 2025to 6 Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult (≥18 years old) having consulted the emergency department or been diagnosed with TIA during the period from January 1, 2024, to December 12, 2024 (records will be compiled via coding at the East Rescue regional emergency observatory)
Who may be able to join
- Adult (≥18 years old)
- Having consulted the emergency department or been diagnosed with TIA during the period from January 1, 2024, to December 12, 2024 (records will be compiled via coding at the East Rescue regional emergency observatory)
- TIA will be defined as a sudden, transient neurological deficit that had disappeared by the time of arrival at the emergency department
Who cannot join
- Subjects with a suspected diagnosis of TIA, i.e., with a sudden, transient neurological deficit that had disappeared by the time of arrival at the emergency department.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Service d'Urgences Médico-Chirurgicales Adules - CHU de Strasbourg - France
Strasbourg, 67091
Pierrick LE BORGNE, MD, 33 3.88.12.86.90, Pierrick.LEBORGNE@chru-strasbourg.fr
Mathieu OBERLIN, MD, 33 6.72.07.23.60, mathieu.oberlin@ghso.fr
About this study
Patients presenting a Transient Ischemic Attack (TIA) and admitted to the Emergency Department should be referred to a neurovascular specialist. In recent years, several hospitals have established TIA clinics. These units are day hospitals where all the necessary examinations are performed. Access to this expertise has proven beneficial in reducing cardiovascular morbidity and mortality, particularly the risk of early recurrence. Unfortunately, this access is limited by issues of medical demographics and unequal access to the healthcare system. In practice, this ideal care is not always possible. A portion of the TIA population is at low risk, and diagnostic and therapeutic interventions are limited, not always requiring neurovascular expertise.
The hypothesis of this research is that the management of a patient who has suffered a TIA (additional examinations, treatment, referral) is not linked to their cardiovascular risk and that the performance of additional examinations and therapies is incomplete.
- Keywords
- Transient Ischemic Attack, Cardiovascular Morbidity
- Medical subject headings
- Ischemic Attack, Transient
What is being measured
The primary outcome is the main question the study is designed to answer.
ABCD2 Score
The ABCD2 score is a medical tool used by doctors after a TIA (Transient Ischemic Attack).
The total score ranges from 0 to 7:
- 0-3: low risk
- 4-5: moderate risk
- 6-7: high risk
Measured: Up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jan 2026
- Study start6 Feb 2025
- Primary completionJan 2027 (estimated)
- Study completion6 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Transient Ischemic AttackStudies of the same condition, open and under way.
- More trials run by University Hospital, Strasbourg, FranceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Strasbourg, France
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07339787
- Sponsor's protocol ID
- 9766
- Acronym
- DAITSU
- Status last verified
- Jan 2026
- First submitted
- 5 Jan 2026
- Last updated
- 14 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Diagnosis of Transient Ischemic Attacks in the Emergency Department
- ClinicalTrials.gov ID
- NCT07339787
- Acronym / sponsor ID
- DAITSU / 9766
- Keywords
- Transient Ischemic Attack, Cardiovascular Morbidity
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- University Hospital, Strasbourg, FranceUniversity, hospital or other
- Study start
- 6 Feb 2025 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- 6 Jan 2027 (estimated)
- First posted
- 14 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients presenting a Transient Ischemic Attack (TIA) and admitted to the Emergency Department should be referred to a neurovascular specialist. In recent years, several hospitals have established TIA clinics. These units are day hospitals where all the necessary examinations are performed. Access to this expertise has proven beneficial in reducing cardiovascular morbidity and mortality, particularly the risk of early recurrence. Unfortunately, this access is limited by issues of medical demographics and unequal access to the healthcare system. In practice, this ideal care is not always possible. A portion of the TIA population is at low risk, and diagnostic and therapeutic interventions are limited, not always requiring neurovascular expertise.
The hypothesis of this research is that the management of a patient who has suffered a TIA (additional examinations, treatment, referral) is not linked to their cardiovascular risk and that the performance of additional examinations and therapies is incomplete.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adult (≥18 years old) having consulted the emergency department or been diagnosed with TIA during the period from January 1, 2024, to December 12, 2024 (records will be compiled via coding at the East Rescue regional emergency observatory)
Key inclusion criteria (3 listed)
- Adult (≥18 years old)
- Having consulted the emergency department or been diagnosed with TIA during the period from January 1, 2024, to December 12, 2024 (records will be compiled via coding at the East Rescue regional emergency observatory)
- TIA will be defined as a sudden, transient neurological deficit that had disappeared by the time of arrival at the emergency department
Key exclusion criteria (1 listed)
- Subjects with a suspected diagnosis of TIA, i.e., with a sudden, transient neurological deficit that had disappeared by the time of arrival at the emergency department.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
ABCD2 Score
Time frame: Up to 12 months
The ABCD2 score is a medical tool used by doctors after a TIA (Transient Ischemic Attack). The total score ranges from 0 to 7: * 0-3: low risk * 4-5: moderate risk * 6-7: high risk
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
Related trials for Transient Ischemic Attack
Active, not recruitingObservational study
Symptomatic Carotid Outcomes Registry
Carotid Stenosis, Ischemic Stroke
Not yet recruitingObservational study
Integrating Wearable Monitoring and Clinical Data for Stroke Early Warning
Stroke, Ischemic Stroke
Not yet recruitingObservational study
PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)
Carotid Atherosclerosis, Carotid Artery Stenosis Asymptomatic
Not yet recruitingPhase 3
Upfront Lipid-Lowering Therapy With Statins Combined With Hybutimibe in Patients With Acute Ischemic Stroke or Transient Ischemic Attack.
Ischemia Stroke, TIA (Transient Ischemic Attack)
Recruiting
Understanding and Enhancing Human Health and Movement
Spinal Cord Injury, Stroke (CVA) or Transient Ischemic Attack
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Transient Ischemic Attack and Cardiovascular Morbidity, run by University Hospital, Strasbourg, France at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Pierrick LE BORGNE, MD (33 3.88.12.86.90, Pierrick.LEBORGNE@chru-strasbourg.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
ABCD2 Score (time frame: Up to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.